Long Term Results on Pancreas Transplant Beyond the Standard Indications, at a Single Center.
1Instuto de Transplante Multiorganico, Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina
2Unidad de Trasplante Renal y Nefrologia, Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina
3Servicio de Cirugia Cardiovascular, Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina.
Meeting: 2016 American Transplant Congress
Abstract number: A52
Keywords: Pancreas transplantation
Session Information
Date: Saturday, June 11, 2016
Session Name: Poster Session A: Clinical Pancreas Transplantation and All Islet Cell Transplantation Topics
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
Introduction: Simultaneous kidney-pancreas (SKP) transplantation has become the best treatment option for patients with end stage renal disease (ESRD) and type 1 diabetes (T1D). In the last two decades type 2 diabetes (T2D) started to be included as a new indication for transplant. Currently it has become between 8.5 and 30% of total number of pancreas transplant performed. Aim: Report our experience in kidney-pancreas transplant. Material and Methods: Retrospective analysis of kidney-pancreas transplant performed between April 2008- Nov 2015. We analyzed recipients´ characteristics, graft function, pancreas, kidney and patients´ survival comparing transplants in T1D and T2D recipients. Results: Forty five patients were transplanted, 34 were T1D (33 SKP and 1 pancreas transplant alone), eleven (24.5%) were T2D received SKP transplant. Patient's characteristics:age, BMI and C-peptide levels pre transplantwere analyzed, only C-peptide was statistical significance, p=0.001. Comparative results of grafts functions are represented in table 1. Patients and graft survival are represented in table 2.
Graft function *p=NS
| *p=NS | T1D/T2D Pre -Tx | T1D/T2D 3 months post-Tx | T1D/T2D 6 months post-Tx | T1D/T2D 1 year post-Tx |
| Glycemia levels mg/dl | 178/123* | 87.2/91.9* | 97.1/97.9* | 100.7/93.9* |
| HbA1C | 8.7/6.5* | 5.5/5.6* | 5.5/5.4* | 5.5/5.8* |
| Creatinine levels mg/dl | – | 1/1.2* | 1.3/1.3* | 1.2/1.1* |
Survival
| T1D patients | T2D patients | P value | |
| Patients survival at 1 and 5 years | 88/88% | 89/74% | NS |
| Pancreas graft survival at 1 and 5 years | 82/82% | 89/74% | NS |
| Kidney graft survival at 1 and 5 years | 85/77% | 89/74% | NS |
.
Conclusion: Under strict selective criteria for pancreas transplant, results in T2D patients are comparable to T1D recipients at our center.
CITATION INFORMATION: Ramisch D, Aguirre N, Moss F, Farinelli P, Fortunato R, Gutierrez L, Barros Schelotto P, Fraguas H, Raffaele P, Gondolesi G. Long Term Results on Pancreas Transplant Beyond the Standard Indications, at a Single Center. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Ramisch D, Aguirre N, Moss F, Farinelli P, Fortunato R, Gutierrez L, Schelotto PBarros, Fraguas H, Raffaele P, Gondolesi G. Long Term Results on Pancreas Transplant Beyond the Standard Indications, at a Single Center. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-results-on-pancreas-transplant-beyond-the-standard-indications-at-a-single-center/. Accessed January 26, 2020.« Back to 2016 American Transplant Congress